{"id":"4c2e1058-8601-5ae3-b5f1-8e848f0a1061","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-perilla-allergy","predicate":"increases_in_recorded_comparison","statement":"RA-enriched perilla extract improved selected symptom responder rates versus placebo.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"cb090f86-c812-5143-9868-815b365250f0","mechanism_event_label":"RA-enriched perilla extract improved selected symptom responder rates versus placebo.","subject":{"id":"30ca7b15-db8f-5b8b-9dfc-62b04e915585","slug":"perilla-ra-enriched-extract","display_name":"RA-enriched Perilla frutescens extract","entity_type_key":"botanical"},"object":{"id":"56eeb815-4a6a-5fb9-b98c-0b9aec5482c2","slug":"human-seasonal-allergy-response","display_name":"Human seasonal rhinoconjunctivitis symptom response","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"cb090f86-c812-5143-9868-815b365250f0","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-perilla-allergy-event","event_type":"experimental_observation","label":"RA-enriched perilla extract improved selected symptom responder rates versus placebo.","description":"### ra-perilla-allergy\n\nRA-enriched perilla extract improved selected symptom responder rates versus placebo.\nItchy nose, watery eyes, itchy eyes and total symptoms; not isolated RA or a demonstrated intracellular mediator.\nModel and exposure: 29 mild-SAR patients, 21 days; reported RA-enriched 200-mg (n=10), 50-mg (n=9), placebo (n=10) groups.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Extract of Perilla frutescens enriched for rosmarinic acid, a polyphenolic phytochemical, inhibits seasonal allergic rhinoconjunctivitis in humans. | 2004 | https://pubmed.ncbi.nlm.nih.gov/14988517/ | https://doi.org/10.1177/153537020422900305 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"30ca7b15-db8f-5b8b-9dfc-62b04e915585","slug":"perilla-ra-enriched-extract","display_name":"RA-enriched Perilla frutescens extract","entity_type_key":"botanical"},"role":"tested factor","stoichiometry":null,"state_label":"Enriched perilla regimen","sequence_order":0,"notes":""},{"entity":{"id":"56eeb815-4a6a-5fb9-b98c-0b9aec5482c2","slug":"human-seasonal-allergy-response","display_name":"Human seasonal rhinoconjunctivitis symptom response","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"increase","sequence_order":1,"notes":""},{"entity":{"id":"6072a4ae-d563-5466-a1b2-6d280255d346","slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"},"role":"standardized extract constituent","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Enriched perilla regimen\", \"comparator\": \"Placebo\", \"endpoint\": \"RA-enriched perilla extract improved selected symptom responder rates versus placebo.\", \"effect_direction\": \"increase\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"29 mild-SAR patients, 21 days; reported RA-enriched 200-mg (n=10), 50-mg (n=9), placebo (n=10) groups.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Rosmarinic acid collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"RA-enriched perilla extract improved selected symptom responder rates versus placebo.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Extract of Perilla frutescens enriched for rosmarinic acid, a polyphenolic phytochemical, inhibits seasonal allergic rhinoconjunctivitis in humans. | https://pubmed.ncbi.nlm.nih.gov/14988517/ | https://doi.org/10.1177/153537020422900305","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference ra-perilla-allergy; Itchy nose, watery eyes, itchy eyes and total symptoms; not isolated RA or a demonstrated intracellular mediator.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"3498ce9c-5f63-5862-9d0e-67a6cb769e84","evidence_kind":"source_excerpt","locator":"Lines 285-291","start_line":285,"end_line":291,"excerpt":"### ra-perilla-allergy\n\nRA-enriched perilla extract improved selected symptom responder rates versus placebo.\nItchy nose, watery eyes, itchy eyes and total symptoms; not isolated RA or a demonstrated intracellular mediator.\nModel and exposure: 29 mild-SAR patients, 21 days; reported RA-enriched 200-mg (n=10), 50-mg (n=9), placebo (n=10) groups.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Extract of Perilla frutescens enriched for rosmarinic acid, a polyphenolic phytochemical, inhibits seasonal allergic rhinoconjunctivitis in humans. | 2004 | https://pubmed.ncbi.nlm.nih.gov/14988517/ | https://doi.org/10.1177/153537020422900305 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","model_system":"29 mild-SAR patients, 21 days; reported RA-enriched 200-mg (n=10), 50-mg (n=9), placebo (n=10) groups.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"606cff22-a6ed-59cd-a84d-87f44c59dc25","stable_key":"import-ca8e9e6a-6953-51ec-b712-2b06398a416d","title":"Rosmarinic acid: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"684b4eab1dc2c0057f679109770af0de9340af5cd933377b590298cf8a752956","revision_id":"4028d9c5-fb17-54c5-b72c-c6d21678a832","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}